Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study from Italy Emphasizing Head and Neck Areas - Top-Institutions - MDSpire

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study from Italy Emphasizing Head and Neck Areas

  • By

  • Luigi Gargiulo

  • Luciano Ibba

  • Matteo Bianco

  • Sara Di Giulio

  • Mario Valenti

  • Gianluca Avallone

  • Martina Zussino

  • Paolo Calzari

  • Angelo Valerio Marzano

  • Antonio Costanzo

  • Silvia Mariel Ferrucci

  • Alessandra Narcisi

  • March 28, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    National Institute of Allergy and Infectious Diseases (NIAID), NIH
    National Institute of Allergy and Infectious Diseases (NIAID), NIH

    Bethesda, MD

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Trials

  • #2

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Dermatology
    • Allergy and Immunology

  • #3

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Dermatology
    • Immunology

  • #4

    Charité – Universitätsmedizin Berlin
    Charité – Universitätsmedizin Berlin

    Berlin, Berlin

    Key Differentiators

    • Dermatology
    • Clinical Immunology

  • #5

    University of Tokyo Hospital
    University of Tokyo Hospital

    Tokyo, Tokyo

    Key Differentiators

    • Dermatology
    • Allergy and Clinical Immunology

Original Source(s)

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study from Italy Emphasizing Head and Neck Areas

  • by Luigi Gargiulo, Luciano Ibba, Matteo Bianco, Sara Di Giulio, Mario Valenti, Gianluca Avallone, Martina Zussino, Paolo Calzari, Angelo Valerio Marzano, Antonio Costanzo, Silvia Mariel Ferrucci, Alessandra Narcisi

  • March 28, 2026

Related Content

Efficacy of Upadacitinib in Treating Atopic Dermatitis in Sensitive Regions: Outcomes from a Multicenter Real-World Study on Hand, Head/Neck, and Genital Involvement

Oral TYK2 Inhibition in Atopic Dermatitis

Phase 2 trial evaluated once-daily oral TYK2 inhibition in adults with moderate to severe AD.

What Causes the Itch in Dermatitis?

Scientists discover the mechanism that drives inflammation and itching in the chronic skin condition

  • February 3, 2026

  • 2 min